The global treatment for rheumatoid arthritis is available in China, with sales of nearly $3 billion in 2019.

On August 9th, Synthesa Pharmaceuticals announced that it had partnered with Permistus to develop and commercialize its autoimmune disease drug Enriushu (Abrasep Injection) in the Chinese mainland market, which also represents Abrasep's official entry into commercial circulation in China.
, Enriushu is the second product to be marketed in rheumatoid arthritis treatment, after Adesin.
Abasip is the first approved T-cell selective co-stimulation immunomodant in the field of global rheumatoid arthritis (RA), which binds to CD80/CD86 on the surface of the antigen-present cell, prevents the latter from interacting with the T-cell surface CD28, inhibits the active T-cells induced by their own antigens, weakens their downstream inflammatory response, and plays a therapeutic role.
in the field of rheumatoid arthritis, the efficacy of rheumatoid arthritis-positive patients is better than that of ACPA-negative patients.
was approved in the U.S. in 2005 and has global sales of nearly $3 billion in 2019.
, it is understood that in 2013, Synthesa Pharmaceuticals and Baishi Meishi Guibao reached a strategic cooperation, responsible for Enriushu in Chinese mainland's clinical research and development and commercialization of the market.
January 2020, Enriushu was approved for listing by the National Drug Administration (NMPA).
according to the cooperation agreement between Synyder Pharmaceuticals and Pershing MeishiGuibao, Synyder Pharmaceuticals is responsible for Chinese mainland's clinical research and commercialization.
data show that rheumatoid arthritis (RA) is a common chronic autoimmune disease, patients with many diseases, long course of disease, moderate to severe patients and co-existing diseases.
rheumatoid arthritis not only affects the patient's physical ability, quality of life and social participation, but also brings great financial burden to the patient's family and society.
data show that there are about 6 million RA patients in our country.
but our country still faces the situation of "lack of medicine and medicine" in RA treatment.
according to a survey data of more than 30,000 rheumatoid arthritis patients in China, the application of related biological agents in China is only about 10%, and the application of small molecular compounds is less than 1%.
to this, at the end of 2019, the Health And Health Commission issued a paper requiring each hospital to be equipped with rheumatology immunology, which will enable more rheumatoid patients in the future to be better treated.
is undoubtedly an important factor affecting patient choice.
, it is understood that previously including Adamu monoanti, toad monodrion and other imported drugs are self-cost drugs, due to the need for long-term use, many patients can not afford.
but with more and more biological drugs in recent years into the medical insurance, greatly reducing the burden of patients, the domestic market for wind-related drugs is expected to get faster growth.
and Abap's entry, or let the domestic self-exemption market competition more intense.
, it was revealed that the current price of Abrasip is 6000 yuan / month, the first sound pharmaceutical industry for Abrasep equipped with about 60 medical professional team to promote.
the future, the first sound pharmaceutical industry in the rheumatoid autoimmune line will be equipped with 1500 franchise extension personnel, and strive to fully cover all rheumatology or combined rheumatology at the county level.
industry believes that with changes such as the state's health-care directory, it could help such patients "get and afford" innovative drugs.
's pricing is not significant compared to the varieties in the health-care catalog, or paves the way for subsequent price cuts into health-care.
.